Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status.
Aged
Aging
/ physiology
Alzheimer Disease
/ genetics
Apolipoprotein E4
/ genetics
Apolipoproteins E
/ genetics
Cognition
/ drug effects
Cognitive Dysfunction
/ genetics
Diabetes Mellitus, Type 2
/ drug therapy
Dipeptidyl-Peptidase IV Inhibitors
/ therapeutic use
Female
Genotype
Humans
Hypoglycemic Agents
/ therapeutic use
Male
Metformin
/ therapeutic use
Neuropsychological Tests
/ statistics & numerical data
Alzheimer's disease (AD)
apolipoprotein E (APOE)
diabetes
dipeptidyl peptidase-4 inhibitor (DPP4 inhibitor)
memory
metformin
sulfonylurea
thiazolidinedione
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
05
03
2020
revised:
30
06
2020
accepted:
07
07
2020
pubmed:
18
8
2020
medline:
12
11
2021
entrez:
18
8
2020
Statut:
ppublish
Résumé
Few studies have examined memory decline among patients with type 2 diabetes using different oral hypoglycemic drugs. Participants with normal cognition (NC) or Alzheimer's disease (AD) dementia using a hypoglycemic medication (2005 to 2019) were identified from the National Alzheimer's Coordinating Center database. Delayed memory was assessed using the Wechsler Memory Scale Revised-Logical Memory test. Associations between oral drug classes and memory over time were examined using mixed-effects models with inverse probability treatment weights. In NC (n = 1192), metformin use was associated with better memory performance over time, whereas in AD (n = 807), dipeptidyl peptidase-4 (DPP4) inhibitor use was associated with a slower rate of memory decline. Interaction effects suggested greater benefit associated with DPP4 inhibitor use among APOE ε4 carriers. Associations between different oral hypoglycemic drugs and memory change were not consistent between cognitively normal elderly and those with AD dementia. APOE ε4 genotype modified some relationships.
Identifiants
pubmed: 32803865
doi: 10.1002/alz.12161
pmc: PMC7754496
doi:
Substances chimiques
Apolipoprotein E4
0
Apolipoproteins E
0
Dipeptidyl-Peptidase IV Inhibitors
0
Hypoglycemic Agents
0
Metformin
9100L32L2N
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1663-1673Subventions
Organisme : NIA NIH HHS
ID : P50 AG005142
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG010133
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG047266
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG008017
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG010161
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG025688
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005133
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005138
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG047366
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG019610
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG028383
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG013854
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG053760
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066444
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062428
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG010124
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG023501
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005146
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062421
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG035982
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG008702
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG016976
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG008051
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005681
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG013846
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG047270
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062429
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005136
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG049638
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG012300
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062422
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG016573
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062715
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG010129
Pays : United States
Organisme : CIHR
ID : PJT-159711
Pays : Canada
Informations de copyright
© 2020 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Diabetes Care. 2019 Jan;42(Suppl 1):S90-S102
pubmed: 30559235
Pharmacogenomics J. 2006 Jul-Aug;6(4):246-54
pubmed: 16446752
J Clin Exp Neuropsychol. 1998 Jun;20(3):339-52
pubmed: 9845161
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
J Alzheimers Dis. 2016;51(4):1197-208
pubmed: 26967226
Nat Rev Neurol. 2013 Feb;9(2):106-18
pubmed: 23296339
JAMA. 2020 Jan 28;323(4):297-299
pubmed: 31913419
Ann Transl Med. 2018 Jun;6(12):255
pubmed: 30069457
Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):210-6
pubmed: 17132964
Biochim Biophys Acta. 2015 May;1853(5):1046-59
pubmed: 25667085
J Pharm Pharmacol. 2013 Dec;65(12):1773-84
pubmed: 24117480
J Diabetes Complications. 2013 Sep-Oct;27(5):485-91
pubmed: 23680059
Pharmacol Biochem Behav. 2012 Jun;101(4):564-74
pubmed: 22425595
Arch Gerontol Geriatr. 2019 Sep - Oct;84:103896
pubmed: 31204117
J Gerontol A Biol Sci Med Sci. 2014 Sep;69(9):1122-31
pubmed: 24671867
Eur J Endocrinol. 2019 Nov;181(5):499-507
pubmed: 31437816
Alzheimer Dis Assoc Disord. 2018 Oct-Dec;32(4):351-358
pubmed: 30376508
PLoS One. 2019 Feb 15;14(2):e0212293
pubmed: 30768625
Diabetes Res Clin Pract. 2017 Jan;123:192-198
pubmed: 28056430
J Alzheimers Dis. 2016;51(2):501-14
pubmed: 26890736
Biol Psychiatry. 2010 Mar 15;67(6):505-12
pubmed: 19358976
Neuropharmacology. 2013 Sep;72:291-300
pubmed: 23603201
Neurobiol Aging. 2010 Sep;31(9):1503-15
pubmed: 18950899
J Alzheimers Dis. 2018;65(4):1225-1236
pubmed: 30149446
Neurology. 1993 Feb;43(2):250-60
pubmed: 8094895
Diabetologia. 2006 Sep;49(9):2153-61
pubmed: 16830140
Cochrane Database Syst Rev. 2002;(4):CD003804
pubmed: 12519608
FASEB J. 2019 Jun;33(6):7748-7757
pubmed: 30894020
Cell Death Dis. 2012 Dec 20;3:e448
pubmed: 23254291
Mol Neurobiol. 2017 Oct;54(8):6074-6084
pubmed: 27699599
Diabetes Care. 2010 Aug;33(8):1706-11
pubmed: 20435794
Diabetes Care. 2014 Oct;37(10):2884-94
pubmed: 25249673
J Alzheimers Dis. 2019;68(4):1415-1427
pubmed: 30909226
Aging (Albany NY). 2016 Aug;8(8):1718-34
pubmed: 27509335
Alzheimers Dement. 2020 Dec;16(12):1663-1673
pubmed: 32803865
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
Int J Geriatr Psychiatry. 2018 Aug;33(8):1114-1120
pubmed: 29873112
Pharm Res. 2017 Dec;34(12):2614-2627
pubmed: 28589443
Exp Gerontol. 2010 Mar;45(3):202-7
pubmed: 20005285
Brain Res. 2016 Aug 1;1644:149-60
pubmed: 27174003
Int J Mol Sci. 2019 May 23;20(10):
pubmed: 31126115
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Dement Geriatr Cogn Disord. 2010;30(2):131-46
pubmed: 20733306
Curr Alzheimer Res. 2011 Aug;8(5):592-606
pubmed: 21592048
Dement Geriatr Cogn Dis Extra. 2015 Feb 20;5(1):51-63
pubmed: 25852732
Endocr Rev. 2014 Dec;35(6):992-1019
pubmed: 25216328